진단되지 않은 근육병 환자를 대상으로 시행한 늦은 발병 폼페병의 다기관 표적집단선별검사
Multicenter Targeted Population Screening of Late Onset Pompe Disease in Unspecified Myopathy Patients in Korea
6
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Pompe disease is a rare autosomal recessive disorder caused by the deficiency of a lysosomal enzyme, acid alpha-glucosidase (GAA). Early diagnosis and initiation of treatment with enzyme replacement therapy have remarkable effects on the prognosis of Pompe disease. We performed the expanded screening for late onset Pompe disease (LOPD) at eight centers in Korea. Methods: From September 1, 2015, GAA activity were measured from both dried blood spot (DBS) and mixed leukocyte for 188 available patients. For 12 patients with low GAA activity, we performed Sanger sequencing of GAA gene. Results: Among 188 patients, 115 were males. The mean of age of symptom onset and diagnosis were 34.3 years and 41.6 years. Among 12 patients with decreased GAA activity, two patients were confirmed to have LOPD with genetic test (c.1316T>A [p.M439K] + c.2015G>A [p.R672Q], c.1857C>G [p.S619R] + c.546G>C [leaky splicing]). Other two patients had homozygous G576S and E689K mutation, known as pseudodeficiency allele. Conclusions: This study is expanded study of LOPD screening for targeted Korean population. We found two patients with LOPD, and the detection rate of LOPD is 1.06%. With application of modified GAA cutoff value (0.4), which was previously reported, there were no false positive results of GAA activity test using DBS. Therefore, it could be an appropriate screening test for LOPD in especially East-Asian population, in which pseudodeficiency allele is frequent.
Abstract
Background: Pompe disease is a rare autosomal recessive disorder caused by the deficiency of a lysosomal enzyme, acid alpha-glucosidase (GAA). Early diagnosis and initiation of treatment with enzyme replacement therapy have remarkable effects on the prognosis of Pompe disease. We performed the expanded screening for late onset Pompe disease (LOPD) at eight centers in Korea. Methods: From September 1, 2015, GAA activity were measured from both dried blood spot (DBS) and mixed leukocyte for 188 available patients. For 12 patients with low GAA activity, we performed Sanger sequencing of GAA gene. Results: Among 188 patients, 115 were males. The mean of age of symptom onset and diagnosis were 34.3 years and 41.6 years. Among 12 patients with decreased GAA activity, two patients were confirmed to have LOPD with genetic test (c.1316T>A [p.M439K] + c.2015G>A [p.R672Q], c.1857C>G [p.S619R] + c.546G>C [leaky splicing]). Other two patients had homozygous G576S and E689K mutation, known as pseudodeficiency allele. Conclusions: This study is expanded study of LOPD screening for targeted Korean population. We found two patients with LOPD, and the detection rate of LOPD is 1.06%. With application of modified GAA cutoff value (0.4), which was previously reported, there were no false positive results of GAA activity test using DBS. Therefore, it could be an appropriate screening test for LOPD in especially East-Asian population, in which pseudodeficiency allele is frequent.
참고문헌 (26)
- van der Ploeg AT, "Pompe's disease", Lancet, 372, pp.1342~1353 (2008)
- Kishnani PS, "A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease", J Pediatr, 148, pp.671~676 (2006)
- van der Ploeg AT, "A randomized study of alglucosidase alfa in late-onset Pompe's disease", N Engl J Med, 362, pp.1396~1406 (2010)
- Park JS, "Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48weeks follow-up", Neurol Sci, 36, pp.599~605 (2015)
- Kishnani PS, "Timing of diagnosis of patients with Pompe disease: data from the Pompe registry", Am J Med Genet A, 161A, pp.2431~2443 (2013)
- Prosser LA, "Using decision analysis to support newborn screening policy decisions: a case study for Pompe disease", MDM Policy Pract, 3, pp.2381468318763814~ (2018)
- Chien YH, "Pompe disease in infants: improving the prognosis by newborn screening and early treatment", Pediatrics, 124, pp.e1116~e1125 (2009)
- Chien YH, "Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening", J Pediatr, 158, pp.1023~1027.e1 (2011)
- Chien YH, "Early pathologic changes and responses to treatment in patients with later-onset Pompe disease", Pediatr Neurol, 46, pp.168~171 (2012)
- Labrousse P, "Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program", Mol Genet Metab, 99, pp.379~383 (2010)
- Kumamoto S, "High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population", Mol Genet Metab, 97, pp.190~195 (2009)
- Lee JH, "Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population", Neuromuscul Disord, 27, pp.550~556 (2017)
- Jack RM, "The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease", Genet Med, 8, pp.307~312 (2006)
- Huie ML, "Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions", deletions in the acid alpha-glucosidase locus of patients of differing phenotype, 1998, pp.244, 921~927
- Park YE, "Two new missense mutations of GAA in late onset glycogen storage disease type II", J Neurol Sci, 251, pp.113~117 (2006)
- Maimaiti M, "Silent exonic mutation in the acid-alpha-glycosidase gene that causes glycogen storage disease type II by affecting mRNA splicing", J Hum Genet, 54, pp.493~496 (2009)
- Savarese M, "Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease", Neuromuscul Disord, 28, pp.586~591 (2018)
- Preisler N, "Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies", Mol Genet Metab, 110, pp.287~289 (2013)
- Spada M, "Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia", Mol Genet Metab, 109, pp.171~173 (2013)
- Palmio J, "Screening for late-onset Pompe disease in Finland", Neuromuscul Disord, 24, pp.982~985 (2014)
- Gutierrez-Rivas E, "Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: a Spanish cohort", Neuromuscul Disord, 25, pp.548~553 (2015)
- Lukacs Z, "Prevalence of Pompe disease in 3,076 patients with hyper-CKemia and limb-girdle muscular weakness", Neurology, 87, pp.295~298 (2016)
- Musumeci O, "LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population", J Neurol Neurosurg Psychiatry, 87, pp.5~11 (2016)
- Hansen JS, "Screening for late-onset Pompe disease in western Denmark", Acta Neurol Scand, 137, pp.85~90 (2018)
- Gokyigit MC, "A database for screening and registering late onset Pompe disease in Turkey", Neuromuscul Disord, 28, pp.262~267 (2018)
- Jung KS, "KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing", Database (Oxford), 2020, pp.baz146~ (2020)